Scheduled for May 8 at 1 pm ET, the conversation will include Morgan Cheatham, head of healthcare and life sciences at Breyer Capital, Gurdane Bhutani, founder and managing partner of MBX Capital, and will be moderated by Mercury Head of Healthcare and Life Sciences Ben Kromnick.
The $6.5 billion raised by biopharmaceutical companies in the first quarter of 2025 is down nearly 20% year over year, according to a report from GlobalData. The firm says investors continue to favor later-stage companies with clinical data.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
MedCity INVEST is a boutique healthcare investor conference scheduled for May 20-21 at the Willis Tower in Chicago. Register today!
Sign up today and and join us on May 8th where we'll explore how a banking platform approach could be a resource for the needs of entrepreneurs across biotech, diagnostics, and other life science companies.
Etiome’s precision medicine approach introduces a temporal component to treating disease — drugs developed specifically to treat disease at particular points in time even before symptoms show. The Flagship Pioneering startup’s approach offers the potential to prevent disease; in cases where disease is already present, Etiome aims to halt or even reverse it.
Even the most promising medical advancements struggle to take off in real-world settings without clinician buy-in. Here are some key factors that affect clinician adoption and ways healthtech companies can better position their innovations for success.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission.
A webinar on May 8th will explore how a banking platform approach could be a resource for the needs of entrepreneurs across biotech, diagnostics, and other life science companies.
Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology.
Merida Biosciences is developing antibody-like drugs designed to selectively eliminate disease-driving autoantibodies while sparing healthy components of the immune system. Graves' disease, which stems from the immune system's attack on the thyroid gland, is the startup’s lead disease target.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech's Series B round will finance clinical tests of two programs, each addressing a different stage of the disease.
At the MedCity INVEST conference May 20-21 in Chicago, the startups will take part in the Pitch Perfect contest, pitching their technology and services to investor judges.
MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under a new joint venture the biotech is forming with Hologen, a generative AI startup. The joint venture has up to $230 million in committed capital; MeiraGTx gets additional cash for its pipeline.
Charity Tarn, an investor with Arboretum Ventures, will be one of the investor judges for the Pitch Perfect contest at INVEST in Chicago May 20-21. Register today!
Sofinnova Partners aims to invest in 50 to 60 new companies in the life sciences. The infusion of new capital brings the VC firm’s assets under management to more than €4 billion.